שווי פעילות לרווח לפני ריבית, מסים ופחת TC BioPharm (TCBP)

The development of TC Biopharm (TCBP) relies on successful trial phases of cell-based therapies, while cash reserves for testing remain sufficient. The technology stack is based on automated bioreactors that eliminate manual labor in T-cell cultivation. This chart of the share price, with an EV/EBITDA ratio of , is available below. The operating model involves outsourcing production and research to third-party contractors to minimize capital expenditures.

The ratio correlates the total enterprise value, including net debt, with operating profit before taxes and amortization, measuring the payback period of assets. This metric allows for the identification of company undervaluation by excluding the impact of debt load and tax regimes. For TC Biopharm (TCBP), logistics disruptions and sanctions are hindering drug development, which is reflected in the business's EV/EBITDA history as a risk of stagnating cash flows.